Cholinesterase Inhibitors (ChEIs) are a class of medications that work to enhance neurotransmission in the brain by way of inhibition of the enzyme acetylcholinesterase. This enzyme breaks down acetylcholine, a chemical messenger that relays signals between nerve cells and is responsible for many of the processes that keep our bodies functioning on an atomic level. While acetylcholine is used to regulate a wide variety of bodily processes, it’s most heavily associated with the functioning of the parasympathetic nervous system, which is responsible for regulating unconscious functions like heart rate, restful sleep, and digestion. When acetylcholine levels in the brain are low, the parasympathetic nervous system’s processes become disrupted. This leads to a variety of issues, including headache, confusion, nausea, and muscle weakness. ChEIs serve to alleviate these symptoms by inhibiting the enzyme acetylcholinesterase, allowing acetylcholine levels to increase and restoring balance to the parasympathetic nervous system. ChEIs are most commonly prescribed to those suffering from Alzheimer’s disease, dementia, or other cognitive impairments due to depleted levels of acetylcholine in the brain. They are also sometimes used to treat Parkinson’s disease, glaucoma, bipolar disorder, and depression. Though there is some debate as to the efficacy of ChEIs in treating mental health conditions, studies have been conducted that suggest they can be beneficial for those seeking relief from depression and anxiety. ChEIs have a variety of potential side effects, including nausea, vomiting, increased saliva production, diarrhea, fatigue, and blurred vision. Rarely, they can cause severe allergic reactions that can be life-threatening. As such, it is important to speak with a doctor before taking a ChEI. As with all medications, it is important to read and follow the prescription instructions in order to minimize the potential for severe reactions.
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : The role of beliefs, perception, and behavioural patterns in the evolution of psychophysical disorders
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States
Title : Cervical stenosis-induced chronic cerebrospinal fluid flow restriction as a contributing cause of dementia
Joe Sam Robinson, Mercer University, United States